Improved Exercise Capacity and Ischemia 6 and 12 Months After Transendocardial Injection of Autologous Bone Marrow Mononuclear Cells for Ischemic Cardiomyopathy

Abstract

Background-We recently reported the safety and feasibility of autologous bone marrow mononuclear cell (ABMMNC) injection into areas of ischemic myocardium in patients with end-stage ischemic cardiomyopathy. The present study evaluated the safety and efficacy of this therapy at 6-and 12-month follow-up. Methods and Results-Twenty patients with 6-and 12-month follow-up (11 treated subjects; 9 controls) were enrolled in this prospective, nonrandomized, open-label study. Complete clinical and laboratory evaluations as well as exercise stress (ramp treadmill), 2-dimensional Doppler echocardiography, single-photon emission computed tomography (SPECT) perfusion scanning, and 24-hour Holter monitoring were performed at baseline and follow-up. Transendocardial delivery of ABMMNCs was performed with the aid of electromechanical mapping to identify viable myocardium. Each patient received 15 ABMMNC injections of 0.2 mL each. At 6 and 12 months, total reversible defect, as measured by SPECT perfusion scanning, was significantly reduced in the treatment group as compared with the control group. At 12 months, exercise capacity was significantly improved in the treatment group. This improvement correlated well with monocyte, B-cell, hematopoietic progenitor cell, and early hemapoietic progenitor cell phenotypes. Conclusions-The 6-and 12-month follow-up data in this study suggest that transendocardial injection of ABMMNCs in patients with end-stage ischemic heart disease may produce a durable therapeutic effect and improve myocardial perfusion and exercise capacity.

Effect of intramyocardial bone marrow cell injection on diastolic function in patients with chronic myocardial ischemia

“…The mechanism underlying improvement of systolic and diastolic function after bone marrow cell transplantation could be related to promotion of angiogenesis, as proposed by both preclinical and clinical studies (2,5,6,15). Patients in the current study had advanced coronary artery disease and stress-inducible myocardial ischemia, resulting in mild diastolic dysfunction.…”

Proinflammatory Stem Cell Signaling in Cardiac Ischemia

“…They also showed modest but significant benefits with regard to improved left ventricular ejection fraction (LVEF), decreased infarct size, and reduced frequency of recurrent ischemic events or need for intervention. Trials of stem cell therapy for chronic postinfarction heart failure also demonstrated improvements in natriuretic peptide levels, exertional capacity, and mortality at longer than 1 year of follow-up (7,107). However, the benefit, at least in the acute setting, may be limited, as the LVEF recovery did not persist at 18 months of follow-up in the BOOST study (94).…”

Progress and prospects: Cell based regenerative therapy for cardiovascular disease

“…In addition, mean ejection fraction was improved and systolic volumes were favorably reduced. 8,73 The improved perfusion may indicate that the principal effect of cell transfer was stimulation of angiogenesis leading to improved cardiac performance as a secondary effect.…”